Signaling through OX40 enhances antitumor immunity

Seminars in Oncology

Volumn 37, Issue 5, 2010, Pages 524-532

  Jensen, Shawn M ^a   Maston, Levi D ^a   Gough, Michael J ^a   Ruby, Carl E ^a   Redmond, William L ^a   Crittenden, Marka ^a,b   Li, Yuhuan ^a   Puri, Sachin ^a   Poehlein, Christian H ^a   Morris, Nick ^a   Kovacsovics Bankowski, Magdalena ^a   Moudgil, Tarsem ^a   Twitty, Chris ^a   Walker, Edwin B ^a   Hu, Hong Ming ^a   Urba, Walter J ^a   Weinberg, Andrew D ^a,c   Curti, Brendan ^a   Fox, Bernard A ^a,c  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MONOCLONAL ANTIBODY; OX40 LIGAND; PROTEIN BCL 2; PROTEIN BCL XL; SURVIVIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3;

ADOPTIVE IMMUNOTHERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CYTOKINE RELEASE; DRUG TOLERABILITY; HUMAN; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; TUMOR RECURRENCE;

EID: 78449237498     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.09.013     Document Type: Article

References (70)

1. R. Arens, and S.P. Schoenberger Plasticity in programming of effector and memory CD8 T-cell formation Immunol Rev 235 2010 190 205
2. J.G. Egen, M.S. Kuhns, and J.P. Allison CTLA-4: new insights into its biological function and use in tumor immunotherapy Nat Immunol 3 2002 611 618
3. D.J. Paterson, W.A. Jefferies, and J.R. Green Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts Mol Immunol 24 1987 1281 1290
4. S. Mallett, S. Fossum, and A.N. Barclay Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytesa molecule related to nerve growth factor receptor EMBO J 9 1990 1063 1068
5. + T cells J Immunol 179 2007 5014 5023
6. W.L. Redmond, C.E. Ruby, and A.D. Weinberg The role of OX40-mediated co-stimulation in T-cell activation and survival Crit Rev Immunol 29 2009 187 201
7. P. Bansal-Pakala, B.S. Halteman, M.H. Cheng, and M. Croft Costimulation of CD8 T cell responses by OX40 J Immunol 172 2004 4821 4825
8. I. Gramaglia, A.D. Weinberg, M. Lemon, and M. Croft Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses J Immunol 161 1998 6510 6517
9. R. Baumann, S. Yousefi, D. Simon, S. Russmann, C. Mueller, and H.U. Simon Functional expression of CD134 by neutrophils Eur J Immunol 34 2004 2268 2275
10. J. Zaini, S. Andarini, and M. Tahara OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice J Clin Invest 117 2007 3330 3338
11. C. Liu, Y. Lou, and G. Lizee Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice J Clin Invest 118 2008 1165 1175
12. I. Takeda, S. Ine, and N. Killeen Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells J Immunol 172 2004 3580 3589
13. + regulatory T cells and for expansion of these cells J Immunol 178 2007 2018 2027
14. M.D. Vu, X. Xiao, and W. Gao OX40 costimulation turns off Foxp3+ Tregs Blood 110 2007 2501 2510
15. + T cells J Immunol 179 2007 1427 1430
16. C.E. Ruby, M.A. Yates, and D. Hirschhorn-Cymerman Cutting edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right J Immunol 183 2009 4853 4857
17. Y. Tanaka, T. Inoi, H. Tozawa, N. Yamamoto, and Y. Hinuma A glycoprotein antigen detected with new monoclonal antibodies on the surface of human lymphocytes infected with human T-cell leukemia virus type-I (HTLV-I) Int J Cancer 36 1985 549 555
18. S. Miura, K. Ohtani, and N. Numata Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax Mol Cell Biol 11 1991 1313 1325
19. + T cells with homology to tumor necrosis factor J Exp Med 180 1994 757 762
20. P.R. Baum, R.B. Gayle 3rd, and F. Ramsdell Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34 EMBO J 13 1994 3992 4001
21. D.M. Compaan, and S.G. Hymowitz The crystal structure of the costimulatory OX40-OX40L complex Structure 14 2006 1321 1330
22. S. Flynn, K.M. Toellner, C. Raykundalia, M. Goodall, and P. Lane CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1 J Exp Med 188 1998 297 304
23. Y. Ohshima, Y. Tanaka, H. Tozawa, Y. Takahashi, C. Maliszewski, and G. Delespesse Expression and function of OX40 ligand on human dendritic cells J Immunol 159 1997 3838 3848
24. J.K. Burgess, S. Carlin, and R.A. Pack Detection and characterization of OX40 ligand expression in human airway smooth muscle cells: a possible role in asthma? J Allergy Clin Immunol 113 2004 683 689
25. A. Imura, T. Hori, and K. Imada The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells J Exp Med 183 1996 2185 2195
26. I. Mendel, and E.M. Shevach Activated T cells express the OX40 ligand: requirements for induction and costimulatory function Immunology 117 2006 196 204
27. D. Masopust, and R. Ahmed Reflections on CD8 T-cell activation and memory Immunol Res 29 2004 151 160 (Pubitemid 38822405)
28. J. Song, S. Salek-Ardakani, P.R. Rogers, M. Cheng, L. Van Parijs, and M. Croft The costimulation-regulated duration of PKB activation controls T cell longevity Nat Immunol 5 2004 150 158
29. P.R. Rogers, J. Song, I. Gramaglia, N. Killeen, and M. Croft OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells Immunity 15 2001 445 455
30. J. Song, T. So, M. Cheng, X. Tang, and M. Croft Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion Immunity 22 2005 621 631
31. M. Croft Control of immunity by the TNFR-related molecule OX40 (CD134) Annu Rev Immunol 28 2010 57 78
32. R.A. Prell, D.E. Evans, C. Thalhofer, T. Shi, C. Funatake, and A.D. Weinberg OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent J Immunol 171 2003 5997 6005
33. C.A. Huddleston, A.D. Weinberg, and D.C. Parker OX40 (CD134) engagement drives differentiation of CD4+ T cells to effector cells Eur J Immunol 36 2006 1093 1103
34. Y. Ohshima, L.P. Yang, and T. Uchiyama OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors Blood 92 1998 3338 3345
35. C.E. Ruby, R. Montler, R. Zheng, S. Shu, and A.D. Weinberg IL-12 is required for anti-OX40-mediated CD4 T cell survival J Immunol 180 2008 2140 2148
36. P.R. Rogers, and M. Croft CD28, Ox-40, LFA-1, and CD4 modulation of Th1/Th2 differentiation is directly dependent on the dose of antigen J Immunol 164 2000 2955 2963
37. S.J. Jenkins, G. Perona-Wright, A.G. Worsley, N. Ishii, and A.S. MacDonald Dendritic cell expression of OX40 ligand acts as a costimulatory, not polarizing, signal for optimal Th2 priming and memory induction in vivo J Immunol 179 2007 3515 3523
38. S.K. Lathrop, C.A. Huddleston, P.A. Dullforce, M.J. Montfort, A.D. Weinberg, and D.C. Parker A signal through OX40 (CD134) allows anergic, autoreactive T cells to acquire effector cell functions J Immunol 172 2004 6735 6743
39. W.L. Redmond, M.J. Gough, B. Charbonneau, T.L. Ratliff, and A.D. Weinberg Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist J Immunol 179 2007 7244 7253
40. + memory T cell survival and significantly increases recall responses Eur J Immunol 37 2007 157 166
41. S.L. Gaffen Signaling domains of the interleukin 2 receptor Cytokine 14 2001 63 77
42. + T cell tolerance to an endogenous tumor antigen J Immunol 176 2006 974 983
43. + T regulatory cell inhibition J Immunol 176 2006 2486 2495
44. L. Serghides, J. Bukczynski, and T. Wen Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL J Immunol 175 2005 6368 6377
45. A.D. Weinberg, M.M. Rivera, and R. Prell Engagement of the OX-40 receptor in vivo enhances antitumor immunity J Immunol 164 2000 2160 2169
46. A. Morris, J.T. Vetto, and T. Ramstad Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo Breast Cancer Res Treat 67 2001 71 80
47. S.A. Ali, M. Ahmad, and J. Lynam Anti-tumour therapeutic efficacy of OX40L in murine tumour model Vaccine 22 2004 3585 3594
48. R.E. Sadun, W.E. Hsu, and N. Zhang Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models J Immunother 31 2008 235 245
49. W.L. Redmond, M.J. Gough, and A.D. Weinberg Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo Eur J Immunol 39 2009 2184 2194
50. J. Kjaergaard, J. Tanaka, J.A. Kim, K. Rothchild, A. Weinberg, and S. Shu Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth Cancer Res 60 2000 5514 5521
51. P.Y. Pan, Y. Zang, K. Weber, M.L. Meseck, and S.H. Chen OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases Mol Ther 6 2002 528 536
52. R. Houot, and R. Levy T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy Blood 113 2009 3546 3552
53. H. Nishikawa, and S. Sakaguchi Regulatory T cells in tumor immunity Int J Cancer 127 2010 759 767
54. D. Hirschhorn-Cymerman, G.A. Rizzuto, and T. Merghoub OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis J Exp Med 206 2009 1103 1116
55. B. Valzasina, C. Guiducci, H. Dislich, N. Killeen, A.D. Weinberg, and M.P. Colombo Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR Blood 105 2005 2845 2851
56. S. Piconese, B. Valzasina, and M.P. Colombo OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection J Exp Med 205 2008 825 839
57. C.E. Ruby, and A.D. Weinberg OX40-enhanced tumor rejection and effector T cell differentiation decreases with age J Immunol 182 2009 1481 1489
58. G. Dranoff, E. Jaffee, and A. Lazenby Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proc Natl Acad Sci U S A 90 1993 3539 3543
59. A.L. Marzo, R.A. Lake, and D. Lo Tumor antigens are constitutively presented in the draining lymph nodes J Immunol 162 1999 5838 5845
60. N.J. Nesslinger, R.A. Sahota, and B. Stone Standard treatments induce antigen-specific immune responses in prostate cancer Clin Cancer Res 13 2007 1493 1502
61. + T cells: changing strategies for cancer treatment Blood 114 2009 589 595
62. M.J. Gough, M. Crittenden, and M. Sarff Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control following surgical or radiation therapy of cancer in mice J Immunother 33 2010 798 809
63. H. Yokouchi, K. Yamazaki, and K. Chamoto Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer Cancer Sci 99 2008 361 367
64. L. Apetoh, F. Ghiringhelli, and A. Tesniere Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nat Med 13 2007 1050 1059
65. D.L. Morton Changing concepts of cancer surgery: surgery as immunotherapy Am J Surg 135 1978 367 371
66. J. Kjaergaard, L. Peng, P.A. Cohen, J.A. Drazba, A.D. Weinberg, and S. Shu Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor J Immunol 167 2001 6669 6677
67. A. Song, X. Tang, K.M. Harms, and M. Croft OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen J Immunol 175 2005 3534 3541
68. A.D. Weinberg, C. Thalhofer, and N. Morris Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study J Immunother 29 2006 575 585
69. M. Kovacsovics-Bankowski, E. Walker, K. Floyd, W. Urba, B. Curti, and A.D. Weinberg Increased CD4 and CD8 memory T-cell proliferation after anti-OX40 administration to cancer patients: immunologic assessment of a phase I clinical trial [abstract] J Immunother 32 2009 952
70. N.P. Morris, C. Peters, and R. Montler Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain Mol Immunol 44 2007 3112 3121